Description

Overview

Semax is a synthetic heptapeptide derived from a short ACTH-related sequence and modified for greater stability. Research has examined neurotrophic factors such as BDNF and NGF, dopaminergic and serotonergic signaling, oxidative stress, neuroplasticity, learning, and models of cerebral ischemia. Much of the human clinical literature originates from Russia and nearby regions. Apex should distinguish experimental neuroprotection findings from established U.S. clinical indications.

How It Works

• Neurotrophic signaling: Experimental studies report changes in BDNF, NGF, and pathways involved in synaptic plasticity.
• Monoamine systems: Research examines dopaminergic and serotonergic signaling.
• Ischemic-stress response: Animal and regional clinical studies have explored neuronal survival and recovery after cerebral ischemia.

Research Areas

• Neuroprotection models
• Learning and memory
• Neurotrophic-factor signaling
• Cerebral ischemia research

Research / Study Context

• Animal studies: Behavioral, molecular, and ischemia models measure cognition, neurotrophic factors, and neuronal injury.
• Regional clinical research: Studies have evaluated neurologic recovery and cognitive outcomes, primarily outside the United States.

Key Research Findings

• Semax has meaningful mechanistic literature but limited large multinational trials.
• Most U.S. marketing claims would exceed the strength of the available evidence.
• It is not FDA-approved in the United States.

Related Research

• Selank
• DSIP
• Humanin

Scientific Reference Starter Set

• Peptide Education Hub: Semax profile
• PubMed search: Semax BDNF neuroprotection
• PubMed search: Semax cerebral ischemia